ConductScience.org, home

Paper36975206

Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors.

Ressing M and 11 others. Cancer Rep (Hoboken), 2023. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors. Papers, record 36975206. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36975206

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors.
PubMed
Journal
Cancer Rep (Hoboken)
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.57
iCite
Revised in PubMed
2026-09-20
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ressing MMeikehttps://orcid.org/0000-0001-6326-9005
2Becker CCornelia
3Müller CChristian
4Mahmoudpour SHSeyed Hamidreza
5Calaminus GGabriele
6Langer TThorsten
7Erdmann FFriederike
8Voigt MMathias
9Kaiser MMelanie
10Kaatsch PPeterhttps://orcid.org/0000-0002-8565-0832
11Blettner MMaria
12Spix CClaudia

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Drug Dosage CalculationsMajor topic
Humans
Child
Neoplasms
Algorithms

References59

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112788587Adrenal insufficiency.Lancet2003https://conductscience.org/library/papers/12788587PubMed
210789823Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.Drug Saf2000https://conductscience.org/library/papers/10789823PubMed
322124095Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.J Clin Oncol2012https://conductscience.org/library/papers/22124095PubMed
412637473Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique.J Clin Oncol2003https://conductscience.org/library/papers/12637473PubMed
516965909Role of radiotherapy and chemotherapy in the risk of secondary leukaemia after a solid tumour in childhood.Eur J Cancer2006https://conductscience.org/library/papers/16965909PubMed
68334677Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity.Cancer Treat Rev1993https://conductscience.org/library/papers/8334677PubMed
716895963The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients.J Clin Endocrinol Metab2006https://conductscience.org/library/papers/16895963PubMed
82737789Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects.Int J Clin Pharmacol Ther Toxicol1989https://conductscience.org/library/papers/2737789PubMed
910492065A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.Leuk Lymphoma1999https://conductscience.org/library/papers/10492065PubMed
102194535New cytotoxic drugs in treatment of breast cancer.Acta Oncol1990https://conductscience.org/library/papers/2194535PubMed
1110710274Persistent hypokalemia after successful adrenalectomy in a patient with Cushing's syndrome due to ectopic ACTH secretion: possible role of 11beta-hydroxysteroid dehydrogenase inhibition.J Endocrinol Invest1999https://conductscience.org/library/papers/10710274PubMed
122015395Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.Blood1991https://conductscience.org/library/papers/2015395PubMed
131723369Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.Drugs1991https://conductscience.org/library/papers/1723369PubMed
148329832Temporal and individual variations in the dose of glucocorticoid used for the treatment of salt-losing congenital virilizing adrenal hyperplasia due to 21-hydroxylase deficiency.Acta Paediatr Suppl1993https://conductscience.org/library/papers/8329832PubMed
159792296A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.Br J Haematol1998https://conductscience.org/library/papers/9792296PubMed
1626747086Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy: A Cross-sectional Study.Ann Intern Med2016https://conductscience.org/library/papers/26747086PubMed
1739976936The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review.JAMA Oncol2025https://conductscience.org/library/papers/39976936PubMed
1826304888Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.J Clin Oncol2015https://conductscience.org/library/papers/26304888PubMed
1932779106What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study.J Endocrinol Invest2021https://conductscience.org/library/papers/32779106PubMed
2012531809Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.Blood2003https://conductscience.org/library/papers/12531809PubMed

See all 59 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
37530985Subsequent primary neoplasms after childhood cancer therapy - design and description of the German nested case-control study STATT-SCAR.Cancer Causes Control2024https://conductscience.org/library/papers/37530985PubMed
36975206Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors.Cancer Rep (Hoboken)2023https://conductscience.org/library/papers/36975206PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36975206

GET https://conductscience.org/api/papers/v1/36975206/references?page=2